Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study.
Ian ChauJoon Oh ParkBaek-Yeol RyooChia-Jui YenRonnie PoonDavide PastorelliJean-Frédéric BlancMasatoshi KudoTulio PfifferEtsuro HatanoHyun Cheol ChungKaterina KopeckovaJean-Marc PhelipGiovanni BrandiShinichi OhkawaChung-Pin LiTakuji OkusakaYanzhi HsuPaolo B AbadaAndrew X ZhuPublished in: British journal of cancer (2018)
Treatment with ramucirumab prolonged time to AFP progression, slowed AFP increase and was more likely to induce AFP response. Similar benefits in radiographic progression and response correlated with AFP changes.